Brain activity tests to predict ADHD medication response
Treatments studied
Part of Hormones & metabolism, Mental health clinical trials.
This study looks at how the brain's electrical activity may predict whether a child with ADHD will respond well to methylphenidate (Ritalin). It aims to find biological markers that could help doctors choose the right treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is between 6 and 18 years old.
- Child has been diagnosed with ADHD by a doctor using standard criteria (DSM-5).
- ADHD symptoms are moderate to severe (a doctor’s rating of more than 4 on a 1-7 scale).
- Child has an IQ score above 80.
- Child has never taken any ADHD medication before.
- Child does not have other major conditions like autism, epilepsy, diabetes, or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how methylphenidate (Ritalin) is processed in the body in adults with ADHD, and whether this differs between people with obesity and those without. It aims to help doctors give the right dose to each person.
This study tests whether brain wave recordings (EEG) can help predict how well children with ADHD will respond to stimulant medications. It aims to find the best treatment faster, potentially reducing the guesswork in choosing the right medication.
This study uses brain imaging (MRI) to see how methylphenidate affects brain activity in people with ADHD. It may help doctors better understand how this medicine works and who benefits most.
This Phase 4 study checks whether certain markers change in the brain/body when children with ADHD take methylphenidate (a stimulant). It also compares these markers with healthy children to better understand ADHD.
This study looks at how your genes affect your response to Methylphenidate (a common ADHD medication, excluding the quick-release forms). If you live in Western Canada and are starting this treatment, your participation could help doctors personalize ADHD care in the future.
This Phase 3 study tests how methylphenidate affects brain signals and attention in adults with ADHD, and in adults with mood-related attention problems. It also includes healthy volunteers to compare brain responses during brain scanning.
Hear when a new Methylphenidate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.